title: Activation of protein C in vivo.
abstract: An endothelial cell-associated cofactor that greatly enhances the rate of protein C activation by thrombin has recently been described. The observation that the cofactor binds thrombin with unusually high affinity (K(d) = 0.5 nM) suggested that low level thrombin infusion into dogs might lead to the selective activation of protein C. Infusion of thrombin (1 U/min per kg body wt) into the jugular vein of dogs leads to the formation of a systemic anticoagulant activity within 5 min of starting the infusion. The plasma has a prolonged partial thromboplastin time and Factor X(a) clotting time, but there is no change in the thrombin clotting time. The systemic anticoagulant activity is identified as activated protein C for the following reasons: (a) anti-canine activated protein C IgG antibodies inhibit the anticoagulant activity; (b) the anticoagulant activity can be partially purified from the plasma of dogs infused with thrombin by barium citrate adsorption; (c) the anticoagulant has chromatographic properties on QAE Sephadex indistinguishable from those of activated protein C, and (d) the rate at which this anticoagulant is inhibited in citrated canine plasma is identical to that of canine activated protein C. The in vivo activation of protein C appears to be receptor mediated since it occurs at low thrombin concentration and since it can be progressively inhibited by simultaneous infusion of diisopropylphospho-thrombin with thrombin. The activation of protein C at low levels of thrombin is selective, since neither the platelet count nor the Factor V levels are altered. Thrombin infusion leads to an elevation in circulating plasminogen activator levels. This appears to be mediated through the activation of protein C since coinfusion of diisopropylphospho-thrombin with thrombin inhibits the increase in plasminogen activator levels. Pretreatment of dogs with dicumarol blocks both the formation of anticoagulant activity and the rise in plasminogen activator. When the dicumarol-treated dogs are supplemented with isolated protein C and thrombin is infused, the anticoagulant activity again appears and the circulating levels of plasminogen activator are again elevated. These studies illustrate that low levels of thrombin in vivo can activate protein C, which in turn can inhibit blood coagulation and initiate fibrinolysis by elevating circulating plasminogen activator levels.
mesh_terms: D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D002417:Cattle; D001728:Dicumarol / Q000494:pharmacology; D004285:Dogs; D005165:Factor V / Q000032:analysis; D005170:Factor X; D015951:Factor Xa; D006023:Glycoproteins / Q000096:biosynthesis* / Q000378:metabolism; D007531:Isoflurophate / Q000494:pharmacology; D010960:Plasminogen Activators / Q000032:analysis / Q000096:biosynthesis; D010976:Platelet Count; D011486:Protein C; D013917:Thrombin / Q000008:administration & dosage / Q000494:pharmacology; D013918:Thrombin Time
chemical_list: D006023:Glycoproteins; D011486:Protein C; D007531:Isoflurophate; D001728:Dicumarol; D005165:Factor V; D005170:Factor X; D010960:Plasminogen Activators; D013917:Thrombin; D015951:Factor Xa